CORT
Corcept Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.03 / 10
Outperform
Analyst sentiment is cautiously optimistic: both active analysts rate CORT as 'Strong Buy,' and the historical weighted rating is 4.23, indicating a bullish consensus. Fund-flow analysis shows a good score of 7.82/10, with positive Small and Medium inflows (0.512, 0.504) despite a negative overall trend. This suggests underlying buying interest that could support price action if macro headwinds ease.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-23
InstitutionCanaccord Genuity
Times predicted6
Historical Win Rate50.0%
What is the market sentiment for CORT?
- CORT holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.03/10 (Outperform).
